0 works0 citations0 h-index

David A. Jacobsohn

Center for Cancer and Blood Disorders(US)

Publications by Year

Research Areas

Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia research, Acute Myeloid Leukemia Research, Childhood Cancer Survivors' Quality of Life, Renal Transplantation Outcomes and Treatments

Most-Cited Works

→ National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report(2014)5,286 cited
→ National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report(2005)3,499 cited
→ Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation(2011)622 cited
→ Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report(2006)564 cited
→ Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research(2014)433 cited
→ Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report

(2015)

407 cited

→ Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium(2011)383 cited

→ Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal™) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host Disease in a Compassionate Use Study(2010)323 cited

→ Acute graft versus host disease(2007)293 cited

→ Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)(2019)277 cited